Verastem Oncology
RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).
AVMAPKI FAKZYNJA CO-PACK (RAF/MEK clamp avutometinib plus FAK inhibitor defactinib) received accelerated approval on 8 May 2025 for recurrent KRAS-mutated LGSOC after prior therapy (RAMP 201). Also developing a KRAS G12D inhibitor (VS-7375) and combinations in pancreatic cancer.
Pages like this
not linked directly; found by shared links- TermLow-grade serous ovarian cancer (LGSOC)
Shares RAMP 201, Avutometinib + defactinib, RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- ProductElironrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- CompanyQuanta Therapeutics
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- PersonKevan M. Shokat
Shares KRAS & RAS inhibitors, KRAS, Small-molecule kinase inhibitors, Pancreatic ductal adenocarcinoma.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- PersonAndrew J. Aguirre
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.